Clinical study of cannabidiol in children and adolescents with Fragile X (CONNECT-FX) & Open-Label Extension (CONNECT-FX OLE)

Project Type(s):

Principal Investigator(s):

To evaluate the efficacy of ZYN002 administered as a transdermal gel formulation, for up to 12 weeks, in patients ages 3 to <18 years, in the treatment of symptoms of Fragile X Syndrome (FXS).

Project Period:
December 1, 2019 December 31, 2021

Funding Type(s):
Private company/industry

Zynerba Pharmaceuticals

Geographic Area(s):

Patient Population(s):
Adolescents, Children

Targeted Condition(s):
Autism Spectrum Disorder